GB2584105B - Methods of treating neuropathy - Google Patents

Methods of treating neuropathy Download PDF

Info

Publication number
GB2584105B
GB2584105B GB1907153.9A GB201907153A GB2584105B GB 2584105 B GB2584105 B GB 2584105B GB 201907153 A GB201907153 A GB 201907153A GB 2584105 B GB2584105 B GB 2584105B
Authority
GB
United Kingdom
Prior art keywords
methods
treating neuropathy
neuropathy
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1907153.9A
Other languages
English (en)
Other versions
GB2584105A (en
GB201907153D0 (en
Inventor
Blanchetot Christophe
Borross Peter
Budding Kevin
Hack Eric
Silence Karen
Van De Walle Inge
Van Der Pol Ludo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Priority to GB1907153.9A priority Critical patent/GB2584105B/en
Publication of GB201907153D0 publication Critical patent/GB201907153D0/en
Priority to MX2021014170A priority patent/MX2021014170A/es
Priority to CA3138401A priority patent/CA3138401A1/en
Priority to SG11202112232YA priority patent/SG11202112232YA/en
Priority to EA202193189A priority patent/EA202193189A1/ru
Priority to CN202410047987.6A priority patent/CN118021970A/zh
Priority to JP2021569042A priority patent/JP7607590B2/ja
Priority to NZ781789A priority patent/NZ781789B2/en
Priority to US17/608,637 priority patent/US20250066460A1/en
Priority to EP20729653.4A priority patent/EP3972643B1/en
Priority to CN202080037596.6A priority patent/CN114269382B/zh
Priority to LTEPPCT/EP2020/064234T priority patent/LT3972643T/lt
Priority to PT207296534T priority patent/PT3972643T/pt
Priority to PCT/EP2020/064234 priority patent/WO2020234432A1/en
Priority to AU2020279543A priority patent/AU2020279543A1/en
Priority to DK20729653.4T priority patent/DK3972643T3/da
Priority to EP25159620.1A priority patent/EP4570316A3/en
Priority to PL20729653.4T priority patent/PL3972643T3/pl
Priority to BR112021023198A priority patent/BR112021023198A2/pt
Priority to MA71752A priority patent/MA71752A/fr
Priority to ES20729653T priority patent/ES3035736T3/es
Priority to HUE20729653A priority patent/HUE072743T2/hu
Priority to FIEP20729653.4T priority patent/FI3972643T3/fi
Priority to KR1020217039139A priority patent/KR20220010505A/ko
Publication of GB2584105A publication Critical patent/GB2584105A/en
Priority to IL288010A priority patent/IL288010A/en
Priority to MX2025014486A priority patent/MX2025014486A/es
Application granted granted Critical
Publication of GB2584105B publication Critical patent/GB2584105B/en
Priority to JP2024220534A priority patent/JP2025038109A/ja
Priority to JP2024221343A priority patent/JP2025041724A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1907153.9A 2019-05-21 2019-05-21 Methods of treating neuropathy Active GB2584105B (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy
AU2020279543A AU2020279543A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
DK20729653.4T DK3972643T3 (da) 2019-05-21 2020-05-21 Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier
SG11202112232YA SG11202112232YA (en) 2019-05-21 2020-05-21 Methods of treating neuropathy
EA202193189A EA202193189A1 (ru) 2019-05-21 2020-05-21 Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий
CN202410047987.6A CN118021970A (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
JP2021569042A JP7607590B2 (ja) 2019-05-21 2020-05-21 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
NZ781789A NZ781789B2 (en) 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
US17/608,637 US20250066460A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
PL20729653.4T PL3972643T3 (pl) 2019-05-21 2020-05-21 Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
CN202080037596.6A CN114269382B (zh) 2019-05-21 2020-05-21 用于治疗副蛋白血症性神经病的方法的补体系统的拮抗剂
LTEPPCT/EP2020/064234T LT3972643T (lt) 2019-05-21 2020-05-21 Komplemento sistemos antagonistai, skirti naudoti paraproteineminių neuropatijų gydymo būduose
PT207296534T PT3972643T (pt) 2019-05-21 2020-05-21 Antagonistas do sistema do complemento para utilização em métodos de tratamento de neuropatias paraproteinémicas
PCT/EP2020/064234 WO2020234432A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
MX2021014170A MX2021014170A (es) 2019-05-21 2020-05-21 Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas.
EP25159620.1A EP4570316A3 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
BR112021023198A BR112021023198A2 (pt) 2019-05-21 2020-05-21 Antagonistas do sistema de complemento para uso em métodos de tratamento de neuropatias paraproteinêmicas
EP20729653.4A EP3972643B1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
CA3138401A CA3138401A1 (en) 2019-05-21 2020-05-21 Methods of treating neuropathy
MA71752A MA71752A (fr) 2019-05-21 2020-05-21 Antagonistes du système du complément pour une utilisation dans des procédés de traitement de neuropathies paraprotéiques
ES20729653T ES3035736T3 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
HUE20729653A HUE072743T2 (hu) 2019-05-21 2020-05-21 Komplementrendszer antagonistái paraproteinémiás neuropátiák kezelési eljárásaiban történõ alkalmazásra
FIEP20729653.4T FI3972643T3 (fi) 2019-05-21 2020-05-21 Komplementtijärjestelmän antagonisteja käytettäväksi paraproteinemisten neuropatioiden hoitomenetelmissä
KR1020217039139A KR20220010505A (ko) 2019-05-21 2020-05-21 파라단백혈증 신경병증을 치료하는 방법에 사용하기 위한 보체 시스템의 길항제
IL288010A IL288010A (en) 2019-05-21 2021-11-11 Antagonists to the complement system for the treatment of paraproteinemic neuropathies
MX2025014486A MX2025014486A (es) 2019-05-21 2021-11-18 Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas
JP2024220534A JP2025038109A (ja) 2019-05-21 2024-12-17 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト
JP2024221343A JP2025041724A (ja) 2019-05-21 2024-12-18 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy

Publications (3)

Publication Number Publication Date
GB201907153D0 GB201907153D0 (en) 2019-07-03
GB2584105A GB2584105A (en) 2020-11-25
GB2584105B true GB2584105B (en) 2023-08-02

Family

ID=67385155

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1907153.9A Active GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy

Country Status (22)

Country Link
US (1) US20250066460A1 (https=)
EP (2) EP4570316A3 (https=)
JP (3) JP7607590B2 (https=)
KR (1) KR20220010505A (https=)
CN (2) CN114269382B (https=)
AU (1) AU2020279543A1 (https=)
BR (1) BR112021023198A2 (https=)
CA (1) CA3138401A1 (https=)
DK (1) DK3972643T3 (https=)
EA (1) EA202193189A1 (https=)
ES (1) ES3035736T3 (https=)
FI (1) FI3972643T3 (https=)
GB (1) GB2584105B (https=)
HU (1) HUE072743T2 (https=)
IL (1) IL288010A (https=)
LT (1) LT3972643T (https=)
MA (1) MA71752A (https=)
MX (2) MX2021014170A (https=)
PL (1) PL3972643T3 (https=)
PT (1) PT3972643T (https=)
SG (1) SG11202112232YA (https=)
WO (1) WO2020234432A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
EP4308590A1 (en) 2021-03-18 2024-01-24 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION
CN117597353A (zh) * 2021-03-18 2024-02-23 艾菲洛之克公司 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
JP2025503545A (ja) * 2021-12-30 2025-02-04 アネクソン，インコーポレーテッド ハンチントン病を治療するための組成物及び方法
CA3259060A1 (en) * 2022-07-14 2024-01-18 argenx BV DOSAGE REGIMEN FOR THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY (MMN)
CN121443634A (zh) * 2023-03-07 2026-01-30 克利夫兰诊所基金会 人补体成分2结合分子
WO2025146509A1 (en) * 2024-01-05 2025-07-10 argenx BV Methods of treating multifocal motor neuropathy (mmn)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186599A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
WO2014189378A1 (en) * 2013-05-23 2014-11-27 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof
WO2016073685A1 (en) * 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2019089922A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
CA2662480C (en) * 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
CN110229216B (zh) * 2011-09-07 2023-06-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类肽
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
SG10201804960RA (en) * 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
US11091591B2 (en) * 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
EP3454902A4 (en) * 2016-05-10 2019-10-09 Annexon, Inc. ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
CA3055781A1 (en) * 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186599A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
WO2014189378A1 (en) * 2013-05-23 2014-11-27 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof
WO2016073685A1 (en) * 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2019089922A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
International Journal of Toxicology, 2017, Vol 35 No 6, LANSITA J.A. ET AL., "Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases.", pages 449-462 *
Journal of Neuroimmunology, 2008, Vol 205 No 1-2, VONGSAVANH P. ET AL., "Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre Syndrome", pages 101-104 *
Neurology, 2010, Vol 75 No 9, CATS E.A ET AL., "Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy", pages 818-825 *

Also Published As

Publication number Publication date
US20250066460A1 (en) 2025-02-27
SG11202112232YA (en) 2021-12-30
DK3972643T3 (da) 2025-07-21
IL288010A (en) 2022-01-01
HUE072743T2 (hu) 2025-12-28
JP2025038109A (ja) 2025-03-18
NZ781789A (en) 2025-03-28
JP2025041724A (ja) 2025-03-26
EP4570316A3 (en) 2025-08-13
ES3035736T3 (en) 2025-09-08
GB2584105A (en) 2020-11-25
BR112021023198A2 (pt) 2022-01-04
PT3972643T (pt) 2025-07-15
MA71752A (fr) 2025-05-30
CN118021970A (zh) 2024-05-14
EP3972643A1 (en) 2022-03-30
FI3972643T3 (fi) 2025-07-16
JP7607590B2 (ja) 2024-12-27
LT3972643T (lt) 2025-07-10
AU2020279543A1 (en) 2021-11-25
CN114269382A (zh) 2022-04-01
PL3972643T3 (pl) 2025-09-08
CN114269382B (zh) 2024-02-23
CA3138401A1 (en) 2020-11-26
EA202193189A1 (ru) 2022-03-11
JP2022533705A (ja) 2022-07-25
EP4570316A2 (en) 2025-06-18
KR20220010505A (ko) 2022-01-25
EP3972643B1 (en) 2025-05-14
MX2025014486A (es) 2026-01-07
MX2021014170A (es) 2022-01-04
WO2020234432A1 (en) 2020-11-26
GB201907153D0 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
SG11202112232YA (en) Methods of treating neuropathy
IL275663A (en) Cancer treatment methods
SG11202010830WA (en) Methods of treating phenylketonuria
IL283337A (en) Methods for treating whsc1-overexpressing cancers by inhibiting setd2
SG11202108029XA (en) Methods of treating multiple myeloma
IL284797A (en) Addiction treatment methods
GB201710906D0 (en) Compounds and methods for treating peripheral neuropathy
ZA202203776B (en) Methods of treating epilepsy using the same
IL277981A (en) Cancer treatment methods
IL278759A (en) A method for treating clinical depression
IL287210A (en) Preparations for the treatment of tumors
SG11202010793UA (en) Methods of treating cancer
IL281600B2 (en) Cancer treatment methods
LT3661510T (lt) Elgesio pakitimų gydymo būdai
IL289811A (en) A method for treating cancer
IL290983A (en) Treatment methods
IL288353A (en) Methods for treating cholangiocarcinoma
IL287250A (en) treatment method
ZA202006569B (en) Methods of treating fungal infections
SG11202107017TA (en) Methods of treating cancer
ZA201906319B (en) Methods of treating depression
SG11202005163PA (en) Methods of treating cancer
GB201918853D0 (en) Methods of treatment
SG11202105877YA (en) Method of treatment
SG11202102240YA (en) Methods of treating psoriasis